Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Who can take part

• Histologically confirmed HER-2-positive breast cancer with newly diagnosed brain metastases
• ECOG Performance Status (PS) of 0, 1, 2
• Participants with 1-10 brain metastases will be candidates for T-DXd with SRS at the discretion of the treating radiation oncologist. Intra-cranial metastasis must measure 3 cm or less in the greatest dimension
• Age ≥ 18 years
• Signed written informed consent by patient or legally authorized representative. A signed informed consent must be obtained prior to any study-specific procedures
• Life expectancy of at least 12 weeks
• Any number of prior systemic therapies will be allowed, except T-DXd
• Hemoglobin ≥ 9 g/dL, White blood count ≥ 3.0 × 109/L, Absolute Neutrophil count ≥ 1.5 × 109/L and platelet count ≥ 100 × 109/L
• Serum bilirubin ≤ 1.5 × upper limit of normal (ULN)
• AST and/or ALT ≤ 2 × ULN (≤ 5 × ULN when clearly attributable to the presence of liver metastases)
• Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance > 60 mL/min
• Ability to comply with study procedures and monitoring
• For individuals of childbearing potential, a negative pregnancy test should be obtained within 7 days prior to the start of therapy
• Participants must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before enrollment (to be assessed as clinically indicated)
• Male or female participants of reproductive potential need to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 7 months after last dose of T-DXd; Highly effective and acceptable forms of contraception are:
• Male condom plus spermicide
• Cap plus spermicide
• Diaphragm plus spermicide
• Copper T
• Progesterone T
• Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
• Implants
• Hormone shot or injection
• Combined pill
• Mini-pill
• Patch; Postmenopausal individuals on the study (that will not need contraception) is defined as:
• Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments
• LH and FSH levels in the postmenopausal range for individuals < 50 years
• Radiation-induced oophorectomy with last menses > 1 year ago
• Chemotherapy-induced menopause with > 1 year interval since last menses
• Surgical sterilization (bilateral oophorectomy or hysterectomy); Men and women and members of all races and ethnic groups are eligible for this trial

Who cannot take part

• All toxicities from prior therapies must have resolved to CTCAE v5.0 grade 1 or better by the time of study enrollment
• Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active, or uncontrolled infection, uncontrolled diabetes, second active malignancy) that could cause unacceptable safety risks or compromise compliance with the protocol
• Currently receiving other investigational cancer therapy (with the exception of continuing therapy with GnRH analogues) within 4 weeks prior to start of study treatment
• Ineligible for treatment with T-DXd
• Ineligible for treatment with SRS
• Active or prior documented ILD/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
• Pregnant or breast feeding. The patients should not breast feed for 7 months after stopping the drug
• Prior cranial radiation is not allowed
• Evidence of intra-tumoral or peri-tumoral hemorrhage deemed clinically significant by the treating physician
• Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom, e.g., Crohn's disease, malabsorption, or CTCAE grade > 2 diarrhea of any etiology at baseline
• History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, New York Heart Association (NYHA) functional classification of 3 or 4
• Screen for human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. HIV/HBV/HCV testing per institutional practice
• History of hypersensitivity to T-DXd
• Mean QT interval corrected heart rate (QTc) ≥ 470 ms calculated from 3 electrocardiograms using Fredericia's Correction, calculated as: 8.22 ∛(RR interval)
• LVEF <50%
• Participants with leptomeningeal metastases documented by MRI or CSF evaluation
• Brain metastases within 5 mm of the optic chiasm or optic nerve
• Unable to undergo brain MRI
• History and/or confirmed corneal ulceration
• Use of anthracyclines will be prohibited while on the protocol